Summit Speaker Series: Increasing Gene Therapy Vector Production Using Viral Sensitizer Molecules
Summit Speaker Series - Session Eight
Increasing Gene Therapy Vector Production Using Viral Sensitizer Molecules
Inefficient manufacturing processes can have several important implications during product development. The first and most obvious is cost of goods (COGs), which is driven upwards when GMP compliant material is required. Related are the practical considerations of manufacturing virus using an inefficient process, which means longer times to produce target amounts of virus, more substantial needs in personnel, physical space, and investments in infrastructure. Lastly, there is the issue of maximum feasible dose, where the maximum dose of a manufactured virus given to a patient is limited by the amount of virus that can be produced.
Viral Sensitizers (VSETMs) encompass a proprietary collection of small molecules that enhance the growth of viruses by transiently and efficiently overcoming cellular antiviral defenses. VSEs can be used in a range of applications such as improving virus manufacturing yield, improving tumor infection by oncolytic viruses, or transduction of cells by common gene therapy vectors like AAV, adenovirus, and lentivirus. Owing to different molecular mechanisms through which they operate, VSEs can be combined, adapted, and formulated for specific uses.
SPEAKERS
Dr. Jean-Simon Diallo, Senior Scientist, Ottawa Hospital; Assistant Professor of Biochemistry, Microbiology and Immunology, University of Ottawa; CEO, Virica Biotech
Dr. Elena Godbout, Senior Research Associate, Ottawa Hospital Research Institute
This is a recording of a webinar that took place May 6, 2021.
Visit www.biocanrx.com for more!